✦ LIBER ✦

Safety, Tolerability, and Efficacy Of Hizentra® In Japanese Patients With Primary Immunodeficiency Over 48 Weeks

✍ Scribed by Imai, Kohsuke; Kanegane, Hirokazu; Yamada, Masafumi; Takada, Hidetoshi; Ariga, Tadashi; Kobayashi, Midori; Rojavin, Mikhail; Bexon, Martin; Nonoyama, Shigeaki; Hara, Toshiro; Miyawaki, Toshio

Book ID: 122171312
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 39 KB
Volume: 133
Category: Article
ISSN: 1097-6825
DOI: 10.1016/j.jaci.2013.12.652

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, Tolerability, and Efficacy of Hi

Safety, Tolerability, and Efficacy of Hizentra Over An Extended Period for the Treatment of Primary Immunodeficiency Disease

✍ Nelson, R.P.; Melamed, I.; Stein, M.R.; Wasserman, R.L. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Simvastatin in severe primary hyperchole

Simvastatin in severe primary hypercholesterolemia: Efficacy, safety, and tolerability in 595 patients over 18 weeks

✍ Leon A. Simons 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 599 KB

Safety and Efficacy Of Biweekly Hizentra

Safety and Efficacy Of Biweekly Hizentra® Administration In Patients With Primary Immunodeficiency Diseases: A Retrospective Single-Center Study

✍ Malcolmson, Clare; Jones, Alison 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Efficacy and Safety of Hizentra®, a New

Efficacy and Safety of Hizentra®, a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency

✍ Michael Borte; Malgorzata Pac; Margit Serban; Teresa Gonzalez-Quevedo; Bodo Grim 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 182 KB

Efficacy and safety of Hizentra® in pati

Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy

✍ S. Jolles; E. Bernatowska; J. de Gracia; M. Borte; V. Cristea; H.H. Peter; B.H. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 506 KB

Patients with primary immunodeficiency r

Patients with primary immunodeficiency receiving subcutaneous immune globulin Hizentra maintain health-related quality of life and treatment satisfaction in a multicentre extension study of efficacy, tolerability and safety

✍ Christopher A. Jones; Mikhail Rojavin; Jeffrey S. Baggish 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 500 KB